¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑÇ÷¾×ÇÐȸ Á¦31Â÷ ¸²ÇÁÁ¾¿¬±¸È¸ Ãß°è Á¤±â ½ÉÆ÷Áö¾ö : 2022-10-22

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑÇ÷¾×ÇÐȸ Á¦31Â÷ ¸²ÇÁÁ¾¿¬±¸È¸ Ãß°è Á¤±â ½ÉÆ÷Áö¾ö : 2022-10-22
±³À°ÀÏÀÚ : 2022-10-22
±³À°Àå¼Ò : ¾çÀç aT¼¾ÅÍ 3Ãþ ¼¼°è·Î  
±³À°ÁÖÁ¦ : ´ëÇÑÇ÷¾×ÇÐȸ Á¦31Â÷ ¸²ÇÁÁ¾¿¬±¸È¸ Ãß°è Á¤±â ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¸²ÇÁÁ¾¿¬±¸È¸  
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581  
À̸ÞÀÏ : hematology@kams.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 80¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 30ºÐ  
¼¼ºÎ¼ö°­·á : 0¿ø      
ºñ°í       

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-22  10:00~10:40 Overview of EBV(epstein-barr virus)-associated lymphoid malignancies  ±èÁ¤Çö(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 10-22  10:40~11:20 How to treat ENKTL(Extranodal NK/T Cell Lymphoma) patients  ±è¼®Áø(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 10-22  11:20~12:00 What should we do for chronic active EBV( epstein-barr virus) infection?  ÃÖÀ±¼®(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 10-22  12:00~12:30 Application of CAR-T/NK cell therapy for T-cell lymphomas  ÀÌÁØÈ£(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 10-22  13:30~14:10 Pathology: how to differentiate G3A, G3B FL(follicular lymphomas), and DLBCL(diffuse large B-cell lymphoma)  ¹éÁøÈ£(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 10-22  14:10~14:50 How to treat G3A and G3B FL(follicular lymphomas): induction and maintenance?  Á¶Àçö(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 10-22  14:50~15:30 How to treat BL(burkitt Lymphoma) based on recent data  Á¶Çö¼ö(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 10-22  15:40~16:20 COVID-19: active and passive immunization and treatment of COVID-19 in lymphoma patients  °íÀçÈÆ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 10-22  16:20~16:40 T cell engagers vs. CAR-T for relapsed/refractory DLBCLdiffuse large B-cell lymphoma)  À¯ÄèÇÑ(°¡ÃµÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑÇ÷¾×ÇÐȸ Á¦31Â÷ ¸²ÇÁÁ¾¿¬±¸È¸ Ãß°è Á¤±â ½ÉÆ÷Áö¾ö : 2022-10-22""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´Ü±¹´ëÇб³º´¿ø 2022³â Á¦3ȸ ´Ü±¹ Á·ºÎÁ·°üÀý ¿Ü»ó ½ÉÆ÷Áö¿ò : 2022-10-22
´ÙÀ½±Û Á¦10Â÷ Çѱ¹ÃÖ¼Òħ½ÀÃéÀå¼ö¼ú¿¬±¸È¸ Çмú´ëȸ : 2022-10-22
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20970 °­¿ø 2024³â ´ëÇѼҾƼÒÈ­±â¿µ¾çÇÐȸ Á¦21Â÷ ¿öÅ©¼ó : 2024-06-21 0 33 2024-06-14
20969 ¼­¿ï Á¦23ȸ Çѱ¹Á¤¸Æ°æÀ念¾çÇÐȸ Çмú´ëȸ ¹× 2024 ±¹Á¦Çмú´ëȸ (1ÀÏÂ÷) : 2024-06-21 0 19 2024-06-14
20968 ¼­¿ï ´ëÇѼҾƳ»ºÐºñÇÐȸ 2024³â Á¦1Â÷ Á¤±âÁý´ãȸ(°íÇÁ·Î¶ôƾÇ÷Áõ) : 2024-06-21 0 13 2024-06-14
20967 ¼­¿ï (¿Â¶óÀÎ) 2024³â ´ëÇÑ°øÁߺ¸°ÇÀÇ»çÇùÀÇȸ 2Â÷ ¿Â¶óÀÎ ÇÏ°è Çмú´ëȸ (2ÀÏÂ÷) : 2024-06-21 0 16 2024-06-14
20966 °æ±â ´ëÇÑÁ¾¾ç³»°úÇÐȸ KSMO Annual Academy for young oncologists(1ÀÏÂ÷) : 2024-06-21 0 9 2024-06-14
20965 °æºÏ ´ëÇѽÉÇ÷°üÁßÀçÇÐȸ Á¦43Â÷ ÇÏ°è±¹Á¦Çмú´ëȸ(1ÀÏÂ÷) : 2024-06-21 0 8 2024-06-14
20964 Á¦ÁÖ Á¦ÁÖÇѶ󺴿ø º¹°­°æ ½ÉÆ÷Áö¿ò : 2024-06-21 0 10 2024-06-14
20963 °æ±â ´ëÇÑÀÓ»ó¹Ì»ý¹°ÇÐȸ 2024³âµµ Á¦27Â÷ Çмú´ëȸ(2ÀÏÂ÷) : 2024-06-21 0 12 2024-06-14
20962 Á¦ÁÖ ´ëÇѳúÇ÷°ü³»Ä¡·áÀÇÇÐȸ The 18th Annual Summer Conference on Endovascular Neurosurgical Therapy (ASCENT 2024) 1ÀÏÂ÷ : 2024-06-21 0 12 2024-06-14
20961 ¼­¿ï 2024³â ´ëÇÑÀÇ·áÁ¤º¸ÇÐȸ Ãá°èÇмú´ëȸ (1ÀÏÂ÷) : 2024-06-20 0 9 2024-06-14
20960 ¼­¿ï (¿Â¶óÀÎ) 2024³â Á¦1ȸ ¼­¿ïÀÇ·á¿ø Áö¿ª»çȸ ¿¬¼ö°­Á : 2024-06-20 0 8 2024-06-14
20959 ¼­¿ï (¿Â¶óÀÎ) 2024³â Á¦1ȸ ¼­¿ïÀÇ·á¿ø Áö¿ª»çȸ ¿¬¼ö°­Á : 2024-06-20 0 15 2024-06-14
20958 ¼­¿ï (¿Â¶óÀÎ) 2024³â ´ëÇÑ°øÁߺ¸°ÇÀÇ»çÇùÀÇȸ 2Â÷ ¿Â¶óÀÎ ÇÏ°è Çмú´ëȸ (1ÀÏÂ÷) : 2024-06-20 0 23 2024-06-14
20957 ºÎ»ê ´ëÇѺ´¸®ÇÐȸ ºÎ»ê¿ï»ê°æ³²Áöȸ 6¿ù ¿¬¼ö±³À° : 2024-06-20 0 7 2024-06-14
20956 ¼­¿ï (¿Â¶óÀÎ) 2024 ÀÀ±Þ½ÉÀ忬±¸È¸ ½ÉÀüµµ ½ÉÆ÷Áö¿ò : 2024-06-20 0 7 2024-06-14
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷